

■文献

- 1) Romaguera D, Angquist L, Du H, Jakobsen MU, Forouhi NG, Halkjaer J, et al. Dietary determinants of changes in waist circumference adjusted for body mass index – a proxy measure of visceral adiposity. *PLoS One*. 2010; 5: e11588.
- 2) Parikh S, Pollock NK, Bhagatwala J, Guo DH, Gutin B, Zhu H, et al. Adolescent fiber consumption is associated with visceral fat and inflammatory markers. *J Clin Endocrinol Metab*. 2012; 97: E1451–7.
- 3) Hairston KG, Vitolins MZ, Norris JM, Anderson AM, Hanley AJ, Wagenknecht LE. Lifestyle factors and 5-year abdominal fat accumulation in a minority cohort: the IRAS Family Study. *Obesity (Silver Spring)*. 2012; 20: 421–7.
- 4) De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut–brain neural circuits. *Cell*. 2014; 156: 84–96.3)
Romaguera D, Angquist L, Du H, Jakobsen MU, Forouhi NG, Halkjaer J, et al. Dietary determinants of changes in waist circumference adjusted for body mass index – a proxy measure of visceral adiposity. *PLoS One*. 2010; 5: e11588.
- 5) Sajilata MG, Singhal RS & Kulkarni PR. Resistant Starch—A Review. *Compr Rev Food Sci Food Saf*. 2006; 5: 1–17.
- 6) Clarke B, Liang R, Morell MK, Bird AR, Jenkins CL, Li Z. Gene expression in a starch synthase IIa mutant of barley: changes in the level of gene transcription and grain composition. *Funct Integr Genomics*. 2008; 8: 211–21.
- 7) King RA, Noakes M, Bird AR, M.K. Morell, Topping DL. An extruded breakfast cereal made from a high amylose barley cultivar has a low glycemic index and lower plasma insulin response than one made from a standard barley. *J Cereal Sci*. 2008; 48: 526–530.
- 8) Bird AR, Vuaran MS, King RA, Noakes M, Keogh J, Morell MK, et al. Wholegrain foods made from a novel high-amylose barley variety (Himalaya 292) improve indices of bowel health in human subjects. *Br J Nutr*. 2008; 99: 1032–40.
- 9) Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. *J Biol Chem*. 2004; 279: 12152–62.
- 10) Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. *Diabetes Care*. 2006; 29: 1357–62.
- 11) Satoh H, Fujii S, Tsutsui H. The high-molecular weight (HMW) form of adiponectin is a significant surrogate marker for the prediction of type 2 diabetes mellitus in the Japanese population. *Nutr Metab Cardiovasc Dis*. 2010; 20: e9–10.
- 12) Vasseur F, Helbecque N, Dina C, Lobbens S, Delannoy V, Gaget S, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. *Hum Mol Genet*. 2002; 11: 2607–14.
- 13) Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. *J Biol Chem*. 2003; 278: 40352–63.
- 14) Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. *Nature*. 2011; 473: 174–180.
- 15) Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. *PLoS One*. 2012; 7: e39743.
- 16) Inoue R, Ohue-Kitano R, Tsukahara T, Tanaka M, Masuda S, Inoue T, et al. Prediction of functional profiles of gut microbiota from 16S rRNA metagenomic data provides a more robust evaluation of gut dysbiosis occurring in Japanese type 2 diabetic patients. *J Clin Biochem Nutr*. 2017; 61: 217–221.
- 17) Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ. Growth requirements and fermentation products of *Fusobacterium prausnitzii*, and a proposal to reclassify it as *Faecalibacterium prausnitzii* gen. nov., comb. nov. *Int J Syst Evol Microbiol*. 2002; 52: 2141–2146.
- 18) Song H, Yoo Y, Hwang J, Na YC, Kim HS. *Faecalibacterium prausnitzii* subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. *J Allergy Clin Immunol*. 2016; 137: 852–860.
- 19) Quévrain E, Maubert MA, Michon C, Chain F, Marquant R, Tailhades J, et al. Identification of an anti-inflammatory protein from *Faecalibacterium prausnitzii*, a commensal bacterium deficient in Crohn's disease. *Gut*. 2016; 65: 415–425.

本原稿は、薬理と治療に掲載された以下の論文をもとに、まとめました。

野村 直生、西村 文、三好 孝則、北薊 英一、森田 英利、松井 輝明
機能性大麦 BARLEYmax (Tantangara)の腸内細菌叢を介する抗肥満効果
薬理と治療 2018, 46(12):2099–2110 受理日(2018-10-22), 採択日(2018-11-27)